regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
The composition and destructiveness of SASP depends upon the senescent cell type, the surrounding microenvironment, and the type of stimulus inducing the senescence. Senescent cells are highly metabolically active, producing large amounts of SASP, which is why senescent cells consisting of only 2% or 3% of tissue cells can be a major cause of aging-associated diseases. SASP factors cause non-senescent cells to become senescent. SASP factors induce insulin resistance. SASP disrupts normal tissue function by producing chronic inflammation, induction of fibrosis and inhibition of stem cells. Transforming growth factor beta family members secreted by senescent cells impede differentiation of adipocytes, leading to insulin resistance. SASP factors IL-6 and TNFα enhance T-cell apoptosis, thereby impairing the capacity of the adaptive immune system. SASP factors from senescent cells reduce nicotinamide adenine dinucleotide (NAD+) in non-senescent cells, thereby reducing the capacity for DNA repair and sirtuin activity in non-senescent cells. SASP induction of the NAD+ degrading enzyme CD38 on non-senescent cells (macrophages) may be responsible for most of this effect. By contrast, NAD+ contributes to the secondary (pro-inflammatory) manifestation of SASP. Aged macrophages have a marked increase in SASP components. Bone marrow mesenchymal stem cells have a higher level of cellular senescence in older persons, resulting in a SASP-induced inflammatory environment causing disruption of factors indispensable for lymphocyte survival.
=== Cough === For chronic and acute coughs, a Cochrane review found no strong evidence for or against the use of honey. For treating children, the systematic review concluded with moderate to low evidence that honey helps more than no treatment, diphenhydramine, and placebo at giving relief from coughing. Honey does not appear to work better than dextromethorphan at relieving coughing in children. Other reviews have also supported the use of honey for treating children. The UK Medicines and Healthcare products Regulatory Agency recommends avoiding giving over-the-counter cough and common cold medication to children under six, and suggests "a homemade remedy containing honey and lemon is likely to be just as useful and safer to take", but warns that honey should not be given to babies because of the risk of infant botulism. The World Health Organization recommends honey as a treatment for coughs and sore throats, including for children, stating that no reason exists to believe it is less effective than a commercial remedy.
== Description == The house cricket is typically gray or brownish in color, growing to 16–21 millimetres (0.63–0.83 in) in length. Males and females look similar, but females will have a brown-black, needle-like ovipositor extending from the center rear, approximately the same length as the cerci, the paired appendages towards the rear-most segment of the cricket. On males, the cerci are more prominent.
=== Distribution === After absorption, the alcohol goes through the portal vein to the liver, then through the hepatic veins to the heart, then the pulmonary arteries to the lungs, then the pulmonary veins to the heart again, and then enters systemic circulation. Once in systematic circulation, ethanol distributes throughout the body, diffusing passively and crossing all biological membranes including the blood–brain barrier. At equilibrium, ethanol is present in all body fluids and tissues in proportion to their water content. Ethanol does not bind to plasma proteins or other biomolecules. The rate of distribution depends on blood supply, specifically the cross-sectional area of the local capillary bed and the blood flow per gram of tissue. As such, ethanol rapidly affects the brain, liver, and kidneys, which have high blood flow. Other tissues with lower circulation, such as skeletal muscles and bone, require more time for ethanol to distribute into. In rats, it takes around 10–15 minutes for tissue and venous blood to reach equilibrium. Peak circulating levels of ethanol are usually reached within a range of 30 to 90 minutes of ingestion, with an average of 45 to 60 minutes. People who have fasted overnight have been found to reach peak ethanol concentrations more rapidly, at within 30 minutes of ingestion. The volume of distribution Vd contributes about 15% of the uncertainty to Widmark's equation and has been the subject of much research.
Sources: en.wikipedia.org
Classical contact mechanics is most notably associated with Heinrich Hertz. In 1882, Hertz solved the contact problem of two elastic bodies with curved surfaces. This still-relevant classical solution provides a foundation for modern problems in contact mechanics. For example, in mechanical engineering and tribology, Hertzian contact stress is a description of the stress within mating parts. The Hertzian contact stress usually refers to the stress close to the area of contact between two spheres of different radii. It was not until nearly one hundred years later that Kenneth L. Johnson, Kevin Kendall, and Alan D. Roberts found a similar solution for the case of adhesive contact. This theory was rejected by Boris Derjaguin and co-workers who proposed a different theory of adhesion in the 1970s. The Derjaguin model came to be known as the Derjaguin–Muller–Toporov (DMT) model (after Derjaguin, M. V. Muller and Yu. P. Toporov), and the Johnson et al. model came to be known as the Johnson–Kendall–Roberts (JKR) model for adhesive elastic contact. This rejection proved to be instrumental in the development of the David Tabor and later Daniel Maugis parameters that quantify which contact model (of the JKR and DMT models) represent adhesive contact better for specific materials. Further advancement in the field of contact mechanics in the mid-twentieth century may be attributed to names such as Frank Philip Bowden and Tabor. Bowden and Tabor were the first to emphasize the importance of surface roughness for bodies in contact.
Themes of nature, pioneers, trappers, and traders played an important part in the early development of Canadian symbolism. Modern symbols emphasize the country's geography, northern climate, lifestyles, and the Canadianization of traditional European and Indigenous symbols. The use of the maple leaf as a symbol dates to the early 18th century in New France. The maple leaf is depicted on Canada's current and previous flags and on the arms of Canada. Canada's official tartan, known as the "maple leaf tartan", reflects the colours of the maple leaf through the seasons—green in the spring, gold in the early autumn, red at the first frost, and brown after falling. The arms of Canada are closely modelled after those of the United Kingdom, with French and distinctive Canadian elements replacing or added to those derived from the British version. Other prominent symbols include the national motto, "A mari usque ad mare" ("from sea to sea"), the sports of ice hockey and lacrosse, the beaver, Canada goose, common loon, Canadian horse, the Royal Canadian Mounted Police, the Canadian Rockies, and, more recently, the Indigenous totem pole and Inuksuk. Canadian cuisine items such as Canadian beer, maple syrup, Nanaimo bars, butter tarts, and the Quebec dishes of poutine and tourtière, alongside material items such as tuques, canoes and Hudson's Bay point blanket are considered as uniquely Canadian. Canadian coins feature many of these symbols: the loon on the $1 coin, the coat of arms on the 50¢ piece, and the beaver on the nickel.
A case of major potassium depletion has been attributed to chronic licorice ingestion, and consequently professional herbalists avoid the use of licorice where they recognize that this may be a risk. Black cohosh has been implicated in a case of liver failure. Few studies are available on the safety of herbs for pregnant women, and one study found that use of complementary and alternative medicines is associated with a 30% lower ongoing pregnancy and live birth rate during fertility treatment. Examples of herbal treatments with likely cause-effect relationships with adverse events include aconite (which is often a legally restricted herb), Ayurvedic remedies, broom, chaparral, Chinese herb mixtures, comfrey, herbs containing certain flavonoids, germander, guar gum, liquorice root, and pennyroyal. Examples of herbs that may have long-term adverse effects include ginseng, the endangered herb goldenseal, milk thistle, senna, aloe vera juice, buckthorn bark and berry, cascara sagrada bark, saw palmetto, valerian, kava (which is banned in the European Union), St. John's wort, khat, betel nut, the restricted herb ephedra, and guarana. There is also concern with respect to the numerous well-established interactions of herbs and drugs.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.